GILEAD SCIENCES, INC. is 9.2x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($150.83 B vs $16.35 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NBIX | GILD |
|---|---|---|
| Market cap | $16.35 B | $150.83 B |
| US-listed rank | #695 | #99 |
| Revenue (latest FY) | $2.86B | $29.44B |
| Net income (latest FY) | $478.60M | $8.51B |
| Net margin | 16.7% | 28.9% |
| P/E (trailing FY) | 34.2 | 17.7 |
| SEC filings | 2,097 | 981 |
GILEAD SCIENCES, INC. is 9.2x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($150.83 B vs $16.35 B).
In their latest fiscal years, NEUROCRINE BIOSCIENCES INC reported $2.86B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: NEUROCRINE BIOSCIENCES INC and GILEAD SCIENCES, INC., or browse the full rankings.